1819 related articles for article (PubMed ID: 30696576)
41. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
42. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline.
Eastell R; Rosen CJ; Black DM; Cheung AM; Murad MH; Shoback D
J Clin Endocrinol Metab; 2019 May; 104(5):1595-1622. PubMed ID: 30907953
[TBL] [Abstract][Full Text] [Related]
43. Comparison of radiological and functional outcomes of conservative treatment with teriparatide and denosumab in thoracolumbar osteoporotic vertebral fracture.
Jeon S; Yu D; Kim S; Kim SW; Jeon I
Osteoporos Int; 2024 May; 35(5):795-804. PubMed ID: 38261013
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis.
Merlotti D; Falchetti A; Chiodini I; Gennari L
Expert Opin Pharmacother; 2019 May; 20(7):805-811. PubMed ID: 30856013
[TBL] [Abstract][Full Text] [Related]
45. The Good and the Bad About the 2017 American College of Physicians Osteoporosis Guidelines.
Lagari V; Gavcovich T; Levis S
Clin Ther; 2018 Jan; 40(1):168-176. PubMed ID: 29196083
[TBL] [Abstract][Full Text] [Related]
46. Osteoporosis in older men: recent advances in pathophysiology and treatment.
Laurent M; Gielen E; Claessens F; Boonen S; Vanderschueren D
Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):527-39. PubMed ID: 24054929
[TBL] [Abstract][Full Text] [Related]
47. Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide.
Reginster JY; Hattersley G; Williams GC; Hu MY; Fitzpatrick LA; Lewiecki EM
Calcif Tissue Int; 2018 Nov; 103(5):540-545. PubMed ID: 29951742
[TBL] [Abstract][Full Text] [Related]
48. Evaluation and Treatment of Osteoporosis.
O'Connor KM
Med Clin North Am; 2016 Jul; 100(4):807-26. PubMed ID: 27235616
[TBL] [Abstract][Full Text] [Related]
49. [Once-weekly teriparatide treatment on osteoporosis].
Nakano T
Clin Calcium; 2014 Jan; 24(1):100-5. PubMed ID: 24369286
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of teriparatide in bisphosphonate-pretreated and treatment-naive patients with osteoporosis at high risk of fracture: Post hoc analysis of a prospective observational study.
Yoshiki F; Nishikawa A; Taketsuna M; Kajimoto K; Enomoto H
J Orthop Sci; 2017 Mar; 22(2):330-338. PubMed ID: 28038880
[TBL] [Abstract][Full Text] [Related]
51. New and developing pharmacotherapy for osteoporosis in men.
Gennari L; Bilezikian JP
Expert Opin Pharmacother; 2018 Feb; 19(3):253-264. PubMed ID: 29350069
[TBL] [Abstract][Full Text] [Related]
52. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
[TBL] [Abstract][Full Text] [Related]
53. Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study.
Hansen L; Petersen KD; Eriksen SA; Gerstoft F; Vestergaard P
Osteoporos Int; 2017 Jan; 28(1):321-328. PubMed ID: 27475930
[TBL] [Abstract][Full Text] [Related]
54. Osteoporosis: Common Questions and Answers.
Harris K; Zagar CA; Lawrence KV
Am Fam Physician; 2023 Mar; 107(3):238-246. PubMed ID: 36920813
[TBL] [Abstract][Full Text] [Related]
55. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence.
Chandran M
Arch Endocrinol Metab; 2022 Nov; 66(5):724-738. PubMed ID: 36382762
[TBL] [Abstract][Full Text] [Related]
56. The Association Between Long-Term Bisphosphonate Use and the Risk of Fracture Among Women Aged 50 or Older with Osteoporosis.
Wang CC; Lu HT; Dusetzina SB; Wu CH
J Womens Health (Larchmt); 2016 Jul; 25(7):738-46. PubMed ID: 27096405
[TBL] [Abstract][Full Text] [Related]
57. Osteoporosis in premenopausal women.
Langdahl BL
Curr Opin Rheumatol; 2017 Jul; 29(4):410-415. PubMed ID: 28394826
[TBL] [Abstract][Full Text] [Related]
58. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.
Josse R; Khan A; Ngui D; Shapiro M
Curr Med Res Opin; 2013 Mar; 29(3):205-16. PubMed ID: 23297819
[TBL] [Abstract][Full Text] [Related]
59. Short-term and long-term effects of osteoporosis therapies.
Reid IR
Nat Rev Endocrinol; 2015 Jul; 11(7):418-28. PubMed ID: 25963272
[TBL] [Abstract][Full Text] [Related]
60. Disparities in osteoporosis treatments.
Liu Z; Weaver J; de Papp A; Li Z; Martin J; Allen K; Hui S; Imel EA
Osteoporos Int; 2016 Feb; 27(2):509-19. PubMed ID: 26216226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
